Why the study?
Does the miR-34a-5p/Sirt1/p66shc pathway mediate anthracycline-induced cardiotoxicity in cardiomyocytes, animal models, and patients?
Population
22 adult patients with high-risk diffuse large B-cell lymphoma; Male Sprague-Dawley rats weighing 250±9g…
Comparison
Doxorubicin or epirubicin. vs Baseline; Untreated control or Dox + Dexrazoxane…
Design
Preclinical
Follow-up
16 weeks (patients), 8 weeks (rats)
Authors
Loading...
Identifies a novel mechanistic target for anthracycline-induced cardiotoxicity; leaves.
Does the miR-34a-5p/Sirt1/p66shc pathway mediate anthracycline-induced cardiotoxicity in cardiomyocytes, animal models, and patients?
The miR-34a-5p/Sirt1/p66shc pathway is a key mechanistic driver of anthracycline-induced cardiotoxicity, offering a potential therapeutic target for cardioprotection.
Zhu et al. (2017) studied this question.